Quantifying Skin Disease Burden in Mycosis Fungoides–Type Cutaneous T-Cell Lymphomas

Stevens, Seth R.; Ke, Malcolm S.; Parry, E. J.; Mark, Julie; Cooper, Kevin D.

doi:10.1001/archderm.138.1.42

Cited by 92 publications

(73 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intervening outcomes at 5 months of ECP were defined as follows: complete remission, no evidence of disease on results of physical examination, computed tomographic scans, blood examination for circulating Sézary cells, or abnormal immunophenotype by means of flow cytometry; partial remission, greater than 50% reduction in the skin severity score. 13 Responders are those who achieved a partial or a complete remission, whereas stable disease indicated less than a 50% reduction in the skin severity score. Data were analyzed by 2 and 2-tailed Fisher exact test.…”

Section: Methodsmentioning

confidence: 99%

Circulating CD4+CD7− Lymphocyte Burden and Rapidity of Response

Stevens¹,

Baron²,

Masten³

et al. 2002

Arch Dermatol

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Circulating CD4+CD7− Lymphocyte Burden and Rapidity of Response

Stevens¹,

Baron²,

Masten³

et al. 2002

Arch Dermatol

Self Cite

View full text Add to dashboard Cite

“…The most widely used method for skin scoring is the Severity Weighted Assessment Tool (SWAT) 8,9 or its modification, the mSWAT. 10 This technique involves the direct assessment of the body-surface area (BSA) of each type of MF/SS lesion (palm plus fingers of the patient ϭ approximately 1% BSA) in each of 12 areas of the body, multiplying the sum of the BSA of each lesion type by a weighting factor (patch ϭ 1, plaque ϭ 2, and tumor ϭ 3 or 4) and generating a sum of the subtotals of each lesion subtype (Table 3 There has been much discussion about the appropriate weighting factor for tumors given their prognostic importance.…”

Section: Skin Assessment and Scoringmentioning

confidence: 99%

Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Olsen

Whittaker

Kim

et al. 2011

JCO

564

518

View full text Add to dashboard Cite

Mycosis fungoides (MF) and Sézary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS.

show abstract

“…The modified Severity Weighted Assessment Tool was used for quantitative assessment of disease burden in the skin of all patients. 20,21 Positron emission tomography/computed tomography scans were used to determine activity of mogamulizumab treatment in lymph nodes and viscera of all patients. Finally, MFC was used to monitor the number of circulating CTCL/Sézary cells in peripheral blood based on aberrancies in expression levels of CD3, CD4, CD7, and/or CD26.…”

Section: Disease Assessment and Response Criteriamentioning

confidence: 99%